December 20, 2018
Authored and Edited by Katherine T. Leonard; Shana K. Cyr, Ph.D.
On December 11, 2018, FDA issued draft guidance on questions and answers about the “deemed to be a license” provision of BPCIA. FDA intends the guidance to answer common questions about FDA’s interpretation of the provision.
The questions for which FDA provides answers relate to identification of products subject to the provision; NDAs for biological products submitted on or before the transition date of March 23, 2020; the statutory and regulatory requirements for BLAs; the transition of biological products from the Orange Book to the Purple Book; and designation of a proper name for affected products. For example, FDA explains that it is posting and updating a list of approved NDAs that will be affected by the provision on its website. FDA also explains that on the transition date, it will send letters to sponsors of affected approved NDAs, advising them that the approved NDA no longer exists and that it was deemed to be a BLA. In addition, FDA explains that it will remove affected products from the Orange Book on the transition date and list them in the Purple Book shortly thereafter.
More information about the provision can be found in FDA’s final guidance on its interpretation of the provision and Finnegan’s related IP FDA Blog post.
Readers are encouraged to read the draft guidance, also available on FDA's website.
abbreviated biologic license application (aBLA), Biologic License Application (BLA), Biologics Price Competition and Innovation Act (BPCIA), FDA Guidance, Food and Drug Administration (FDA), new drug application (NDA), Orange Book, Purple Book
Copyright © 2018 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP.
DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. One of our lawyers will be happy to discuss the possibility of representation with you. Additional disclaimer information.
June 10-12, 2024
San Francisco
Lecture
Patent Protection for Software-Related Inventions in Europe and the USA Training Course
June 5, 2024
Hybrid
10th Annual Georgia Asian Pacific American Bar Association Gala
May 29, 2024
Atlanta
Workshop
Life Sciences Workshop: Updates and Key Trends in Pharmaceutical and Biotechnology IP Law
May 2, 2024
Cambridge
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.